Harvard Bioscience (HBIO) Change in Receivables (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Change in Receivables data on file, last reported at -$1.4 million in Q1 2026.

• Change in Receivables for Q1 2026 came in at -$1.4 million, up 2.23% year-over-year; the trailing twelve-month figure through Mar 2026 was $966000.0 (up 156.56% YoY), and the FY2025 annual result was $934000.0, up 195.89% from the prior year.
• Change in Receivables declined to -$1.4 million in Q1 2026 per HBIO's latest filing, from $4.0 million in the prior quarter.
• Over five years, Change in Receivables peaked at $4.0 million in Q4 2025 and troughed at -$2.8 million in Q2 2024.
• A 5-year average of -$413882.4 and a median of -$855000.0 in 2023 frame the typical range for Change in Receivables.
• The sharpest annual moves came in 2022 and 2023: Change in Receivables tumbled 897.32% in 2022, then jumped 161.29% in 2023.
• A 5-year view of Change in Receivables shows it stood at $1.3 million in 2022, then slipped by 26.48% to $941000.0 in 2023, then jumped by 147.5% to $2.3 million in 2024, then surged by 69.86% to $4.0 million in 2025, then sank by 135.54% to -$1.4 million in 2026.
• Business Quant data shows HBIO's Change in Receivables at -$1.4 million in Q1 2026, $4.0 million in Q4 2025, and $210000.0 in Q3 2025.